Prognostic significance of mmp-1, mmp-3, and mthfr genetic polymorphism for evaluation of uterine leiomyoma and adenomyosis progression

Abstract

Carriage of hyperactive alleles of matrix metalloproteinase-1 (MMP-1) gene is associated with enhanced growth of various neoplasias in humans. When studying the frequency of promoter variants of MMP -1 and -3 genes in 170 patients with uterine leiomyoma, significant associations were revealed between low incidence of MMP-1 1G/1G genotype, high growth rates of leiomyoma, multifocal growth and more common adenomyosis development, thus presuming a protective role of MMP-1/1G homozygosity in the development of symptomatic myoma and adenomyosis and growth-promoting effect of the 2G allele. Hence, the promoter genotype of MMP-1 may be considered as possible genetic marker to predict clinical course of the uterine leiomyoma.

Keywords

gene polymorphism / matrix metalloproteinases / leiomyoma / adenomyosis

References

[1] Баранов В.С., Баранова Е.В., Иващенко Т.Э., Асеев М.В. Геном человека и гены «предрасположенности» (Введение в предиктивную медицину). СПб., 2000.

[2] Иващенко Т.Е., Швед Н.И., Крамарева Н.А. и др. Анализ полиморфных аллелей генов, кодирующих ферменты детоксикации фазы I и II у больных с эндометриозом//Генетика 2003. - Vol. 39. - № 4. - Р. 525-529.

[3] Савицкий Г.А., Савицкий А.Г. Миома матки - проблемы патогенеза и патогенетической терапии. СПб - Элби, 2000, 236 с.

[4] Чухловин А.Б., Забелина Т.С., Зубаровская Л.С. и др. Связь промоторного полиморфизма гена коллагеназы-1 с развитием острой реакции «трансплантат против хозяина» при аллогенной трансплантации гемопоэтических стволовых клеток. Мед.Иммунол.- 2003 - т. 5., № 1-2, с. 101-106.

[5] Becker С.М., Bartley J., Mechsner S., Ebert A.D. Angiogenesis and Endometriose//Zentralbl. Gynakol. - 2004. - Vol. 126.

[6] N 4. - P. 252-258.

[7] Bodner-Adler B., Bodner K., Kimberger O. et al. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP- 1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma//Soc. Gynecol. Investig. - 2004. - Vol. 11. -N3-P. 182-186.

[8] Chegini N., Verala J., Luo X. et al. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropinreleasing hormone analogue therapy//J. Soc. Gynecol. Investig. - 2003. - Vol. 10. - N 3. - P. 161-171.

[9] Ghilardi G., Biond., Caputo M. et al. А single nucleotide polymorphism in the MMP-3 promoter enhances breast cancer susceptibility//Cancer Res. - 2002. - Vol. 8 - P. 3820-3823.

[10] Ding L., Xu J., Luo X., Chegini N.J. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells//Clin. Endocrinol. Metab. - 2004. - Vol. 89. - N 11. - P. 5549-5557.

[11] Inagaki N., Ung L., Otani T. et al. Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp//Eur. J. Obstet. Gynecol. Reprod. Biol. - 2003. - Vol. 111. - N 2. - P. 197-203.

[12] Jacques P.. Kalmbach R., Bagley P. et al. The relationship between riboflavin and plasma total homocysteine in the Framingham offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene//Nutritional Epidemiology. - 2001. - P. 283-288.

[13] Johansson N., Ahonen M., Kahari V.M. Matrix metalloproteinases in tumor invasion//Cell.Mol.Life Sci. - 2000. - Vol. 57. - P. 5-15.

[14] Lane D.A., Grant P.G. Role of hemostatic gene polimorphism in venous and arterial thrombotic disease//Blood. - 2000. -Vol. 95. - P. 1517-1532.

[15] Leppert P.C., Baginski T., Prupas C. et al. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium//Fertil. Steril. - 2004. - Vol. 82. - P. 1182-1187.

[16] Olive D.L., Lindheim S.R., Pritts E.A. New medical treatments for endometriosis//Best Pract. Res. Clin. Obstet. Gynaecol.

[17] 2004. - Vol. 18. - N 2. - P. 319-328.

[18] Osteen K.G., Yeaman G.R., Bruner-Tran K.L. Matrix metalloproteinases and endometriosis//Semin. Reprod. Med.

[19] 2003. - Vol. 21. - N 2. - P. 155-164.

[20] Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator plasmin systems in angiogenesis//Arterioscl. Thromb. Vasс. Biol.- 2001. - Vol. 21. - P. 1104-1117.

[21] Ramon L., Gilabert-Estelles J., Castello R. et al. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay//Hum. Reprod. - 2005. - Vol. 20. - N 1. - P. 272-278.

[22] Shan K., Ying W., Jian-Hui Z. et al. The function of the SNP in the MMP1 and MMP3 promoter in susceptibility to endometriosis in China//Mol. Hum. Reprod. - 2005. - Vol. 11. - N 6. - P. 423-427.

[23] Shaw R.W. Gonadotropin hormone-releasing hormone analogue treatment of fibroids//Baillier's Clinical. Obstetrics, Gynaecology. - 1998. - Vol. 12. - N 2. - P. 245-267.

[24] Ye S., Dhillon S., Turner S.J. et al. Invasiveness of cutaneous melanoma is influenced by matrix metalloproteinase 1 gene polymorphism//Cancer Res. - 2001. - Vol. 61. - P. 1296- 1298.

RIGHTS & PERMISSIONS

Eсо-Vector